Selank

• Research themes include GABA-related gene expression, enkephalin-degrading enzymes, BDNF signalling, stress-related behaviour and immunology
• Evidence strength varies by endpoint and is predominantly preclinical; these themes are not clinical benefit claims.

CAS

129954-34-3

Formula

C₃₃H₅₇N₁₁O₉

Molecular weight

751.9 g/mol

Appearance

White to off-white lyophilized powder

Purity

≥ 99.0% · target, verify batch COA

Storage

Store and ship according to the batch-specific COA, SDS and stability statement for the supplied form. Do not transfer storage conditions from a finished product or another salt form; request solution-stability data for the intended matrix before preparing working solutions.

MOQ

1 kit (10 vials) per SKU

Lead time

10–18 days

Selank is the synthetic linear heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), structurally related to the tuftsin sequence and extended with a Pro-Gly-Pro motif. Peer-reviewed literature includes biochemical and animal work plus a PubMed-indexed Russian randomized comparative study of 62 patients with generalized anxiety disorder or neurasthenia. That study compared Selank with medazepam and reported similar anxiolytic effects, but it was small, used an active comparator rather than a placebo, was published in Russian and has not been independently replicated in a geographically diverse program. The independently verifiable human evidence base therefore remains limited. Historical or foreign-market drug use does not establish approval or clinical equivalence for this RUO material.

• Research topics reported in the literature include anxiety-related behaviour, neurotransmission, memory, BDNF signalling and immune pathways
• Human evidence is limited and does not establish a broadly accepted clinical indication for this RUO reagent.

Mechanistic studies report that Selank altered neurotransmission-related gene expression in rat frontal cortex, with partial overlap and time-dependent correlation with GABA treatment. Separate biochemical work reported inhibition of enkephalin degradation, and animal studies reported BDNF-related changes. These results support several hypotheses rather than one established receptor-level mechanism; most evidence is preclinical and should not be extrapolated to efficacy or safety in humans.

• Public literature does not provide a comprehensive, independently replicated long-term human safety dataset
• This material is for qualified laboratory research only and is not a finished drug, sterile preparation or product for human or veterinary administration.

Interactions reported in the literature

• No controlled interaction dataset supports combination recommendations for this RUO material
• Any multi-analyte or co-exposure study requires its own compatibility, assay-interference and safety assessment.

Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount

• 5 mg
• 10 mg
• 11 mg

Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.

Independent test fails? Full refund.

On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep

Ask for the current packet, not a generic certificate

• Begin with the matching batch COA and review the supplied form, tests, specifications and results recorded for that lot
• Request any additional sequence, content, solvent or counterion evidence only when the buyer's written procedure requires it and the scope has been agreed
• HPLC area purity alone does not establish identity, content, sterility, endotoxin status or stability.

Store and ship according to the batch-specific COA, SDS and stability statement for the supplied form. Do not transfer storage conditions from a finished product or another salt form; request solution-stability data for the intended matrix before preparing working solutions.

State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.

• Volkova A, Shadrina M, Kolomin T, et al. Front Pharmacol. 2016;7:31. PMCID PMC4757669, PMID 26924987. In rat frontal cortex, the study assessed 84 neurotransmission-related genes after Selank or GABA exposure; 7 low-expression genes were excluded, 77 were analyzed, 45 changed at 1 hour and 22 at 3 hours. The overall expression-change patterns correlated positively at 1 hour (r = 0.86, p ≤ 0.05) and negatively at 3 hours (r = -0.39, p ≤ 0.05), supporting a GABAergic modulation hypothesis rather than proving a single receptor mechanism.
• Zozulya AA, Kost NV, Sokolov OYu, et al. Bull Exp Biol Med. 2001;131(4):315-317. PMID 11550013, DOI 10.1023/a:1017979514274. Selank dose-dependently inhibited enzymatic hydrolysis of plasma enkephalin in the reported assay (IC50 15 μM); this supports an enkephalinase-related biochemical hypothesis but does not establish clinical efficacy for a supplied RUO lot.
• Zozulya AA, Neznamov GG, Siuniakov TS, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID 18454096. This Russian-language randomized comparative study included 62 patients (Selank n=30; medazepam n=32) with generalized anxiety disorder or neurasthenia and reported similar anxiolytic effects on the stated scales. Its small active-comparator design, limited accessible reporting and lack of broad independent replication constrain generalization and do not establish approval, equivalence or suitability of this RUO material.
• The FDA document Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated May 14, 2026, does not list Selank in Category 1, 2 or 3. FDA previously recorded removal of Selank acetate (TP-7) from Category 2 after receiving information that the nominator intended to nominate a different substance. Removal from a nomination category is not inclusion on the 503A Bulks List, drug approval or authorization for a specific compounded product.

1. 01

   Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia

   Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2008 · peer-reviewed original research (randomized comparative clinical trial)

   Open source
2. 02

   The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity

   Bulletin of Experimental Biology and Medicine · 2001 · peer-reviewed original research

   Open source
3. 03

   Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank

   Regulatory Peptides · 2011 · peer-reviewed original research

   Open source
4. 04

   Antiviral activity of immunomodulator Selank in experimental influenza infection

   Voprosy Virusologii (Problems of Virology) · 2009 · peer-reviewed original research

   Open source
5. 05

   Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission

   Frontiers in Pharmacology · 2016 · peer-reviewed original research

   Open source
6. 06

   Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats

   Bulletin of Experimental Biology and Medicine · 2019 · peer-reviewed original research

   Open source
7. 07

   Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats

   Behavioural Neurology · 2017 · peer-reviewed original research

   Open source
8. 08

   Bulk Drug Substances Nominated for Use in Compounding Under Section 503A

   U.S. Food and Drug Administration · 2026 · official U.S. regulatory process record

   Open source

• How to read a peptide COA without confusing purity, identity and content
• Peptide purity versus peptide content: a buyer’s method map
• Questions to ask a research peptide supplier before the first purchase order